Announcement: Dr. Alan D’Andrea Joined Scientific Advisory Board of Impact Therapeutics
Impact Therapeutics announced that Dr. Alan D’Andrea joined Scientific Advisory Board of the company.
Dr. D’Andrea is internationally known for his research in the area of DNA damage and DNA repair. He is currently the Fuller-American Cancer Society Professor of Radiation Oncology at Harvard Medical School and the Director of the Center for DNA Damage and Repair at the Dana-Farber Cancer Institute. As recipient of numerous academic awards, Dr. D’Andrea is a former Stohlman Scholar of the Leukemia and Lymphoma Society, and serves on their Medical and Scientific Advisory Board. Dr. D’Andrea is a Distinguished Clinical Investigator of the Doris Duke Charitable Trust, and a Fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine. He is also the recipient of the 2012 G.H.A. Clowes Memorial Award from the American Association for Cancer Research. Dr. D’Andrea participates in a wide range of clinical trials, largely focused on ovarian, breast, prostate, and bladder cancers. In 2017, he became the Director of the Susan Smith Center for Women’s Cancer at the Dana-Farber Cancer Institute.
Dr. D’Andrea received his MD from Harvard Medical School, and completed a fellowship in hematology-oncology at the Dana-Farber Cancer Institute and Children's Hospital, and a research fellowship at the Whitehead Institute.
With Dr. Alan D’Andrea joining in, Impact Scientific Advisory Board now have four world class experts including Dr. Douglas Hanahan, Dr. Robert Weinberg and Dr. Andrew Zhu. Impact CEO Dr. Jun Bao said, ”It’s a great honor to have Dr. Alan D’ Andrea on our Scientific Advisory Board. Alan’s cutting-edge knowledge and decades of research experience in DNA damage response area will be very helpful for Impact pipeline product development. We look forward to working together with our SAB members and really making an impact on cancer treatment.”
Impact Therapeutics is a privately held clinical-stage biopharmaceutical company incorporated in Nanjing, China, and dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. Impact has assembled a most comprehensive global DNA damage response (DDR) pipeline of novel drug candidates generated by in-house discovery platform, and is expanding to other novel synthetic lethality targets to broaden its pipeline. Impact has been invested by recognized venture capital firms including Lilly Asia Ventures.